#United States #Irving #Precision Medicine #AI TechBio #Caris Life

Caris Life Sciences Announces Preliminary Financial Results for 2025

Caris Life Sciences, a notable leader in precision medicine and advanced AI technology, has recently shared its preliminary financial outcomes for the fourth quarter and the entire year of 2025. This announcement marks a significant milestone for the company, highlighting revenues and achievements that underscore its position in the healthcare sector.

Fourth Quarter Highlights

For the last quarter of 2025, Caris reported total revenues reaching approximately $281 million, which reflects a remarkable growth of about 116% compared to the same period in 2024. The substantial revenue increase can be attributed to a heightened demand for molecular profiling services, which alone accounted for about $270 million of the total revenue. This was further bolstered by around $11 million from pharmaceutical research and development services.

In total, the company completed 52,700 clinical therapy selection cases in the fourth quarter. This represents a growth of around 20%, comprising 44,150 MI Profile cases and 8,550 Caris Assure cases, showcasing the rising adoption of Caris’ innovative diagnostic solutions in clinical settings.

Full Year Performance

For the full year ending December 31, 2025, Caris experienced a total revenue of approximately $800 million, indicating a 94% increase from 2024. This growth trajectory is impressive, with molecular profiling services generating about $755 million and pharmaceutical research and development contributing an additional $45 million to the overall revenue.

Additionally, the company completed around 199,300 clinical therapy selection cases throughout the year, which marks a 22% increase, combining 170,300 MI Profile cases and 29,000 Caris Assure cases. These results not only showcase the effectiveness of Caris’ offerings but also their critical role in improving patient outcomes through personalized medicine.

Strong Financial Position

As of December 31, 2025, Caris reported a cash position of approximately $802 million, reflecting a net increase of around $43 million from the previous quarter. This solid financial foundation supports Caris’ ongoing initiatives in precision medicine, including expanding its molecular profiling capabilities and enhancing the clinical application of its technologies.

David D. Halbert, the Founder, Chairman, and CEO of Caris Life Sciences, expressed optimism about the company’s progress, stating, "2025 was a breakthrough year for Caris as we became a public company and demonstrated the scale and impact of our comprehensive molecular profiling platform." Halbert emphasized the company’s commitment to expanding clinical adoption and refining its pipeline to set a new standard in precision medicine.

Upcoming Presentation at J.P. Morgan Conference

Caris Life Sciences is set to provide additional insights during a presentation at the 44th Annual J.P. Morgan Healthcare Conference. This event is anticipated to further highlight the company’s recent achievements and strategic goals. Interested parties can access live and recorded webcasts through Caris’ investor relations website.

A Vision for the Future

Caris Life Sciences continues to be at the forefront of precision medicine, leveraging state-of-the-art technologies like advanced AI and machine learning to unravel the complexities of disease management. Through its comprehensive molecular profiling platform, including Whole Exome and Whole Transcriptome Sequencing, Caris aims to redefine healthcare solutions and improve the human condition.

With its headquarters in Irving, Texas, and operations extending internationally, Caris remains committed to delivering cutting-edge diagnostic solutions, transforming healthcare with an emphasis on patient-centered approaches. As they look to the future, the company is poised for continued innovation and growth in the precision medicine landscape.